Category

Client news

In Client News: Crane Venture Partners Leads $30 M Series C For AI Startup

By | Artificial Intelligence, Client news, Entrepreneurs, Investor and VC News, investors, Series C

Congratulations to our client, Crane Venture Partners on leading the Series C $30 Million funding round for London-based Onfido. Onfido uses artificial intelligence algorithms to help websites verify people’s identities by merely using a photo-based identity document and a selfie to curb hackers and security breaches that have exposed personal information of millions of people globally. This is the second round of investment for Onfido following their round of $30 Million including two of our clients Idinvest and Wellington. In an interview with TechCrunch, Scott Sage, co-founder and partner, Crane Venture Partners, said that Onfido is one of the leading data enterprise…

Read More

Bossa Raises $10 Million Series A For Its Simulation Game

By | Client news, Current Affairs, Entrepreneurs, Gaming, Investor and VC News

Summer turns to fall, and our clients continue to show no signs of stopping. In gaming news, we advised London-based Bossa Studios on its $10 Million Series A fundraise ahead of the launch of its upcoming simulation game Worlds Adrift. Atomico led the investment with participation from existing investor, London Venture Partners. Atomico co-founder and partner Mattias Ljungman and executive-in-residence Alexis Bonte, will both join Bossa’s board of directors. In an ongoing validation of the strength of UK and European tech, Bossa will be making use of Improbable’s ground-breaking SpatialOS platform in the creation of Worlds Adrift. The Cambridge-born tech firm has…

Read More

Habito Raises £18.5 Million In A Series B Round Led By Atomico

By | Client news, Current Affairs, Entrepreneurs, Investor and VC News, investors, Startups

JAG Shaw Baker is proud to have advised our client Habito, on their £18.5 Million Series B round led by Atomico. The raise supports Habito, one of the standout ‘PropTech’ companies in the UK, and their vision to leverage the large inefficiencies inherent in the mortgage market. The round brings the total raised by the company to a total of £27m and the funding will be used for marketing and other product development as well as the company’s plans to expand its offering to other parts of the mortgage process such as home and life insurance. Daniel Hegarty, CEO, Habito started the company in 2015. The JAG Shaw Baker team…

Read More

Atomico Leads $30 M Investment Round in AI Chip Company Graphcore

By | Artificial Intelligence, Client news, investors, Knowledge, Partner Insight, Robots

Artificial intelligence (AI) takes another step forward. Graphcore, a UK chip designer that designs chips specifically for AI, recently closed a $30 M round to support their continued expansion. The round was led by our client, Atomico and included existing investors Amadeus Capital, Robert Bosch Ventures Captial, C4 Ventures, Dell Technologies Capital, Draper Esprit Plc, Foundation Capital, Pitango and Samsung Catalyst Fund. Atomico is a London-based venture capital firm founded by Niklas Zennstrom, a co-founder of Skype. AI Everywhere According to a recent Bloomberg article, the investors in the round also included several machine learning experts such as Demis Hassabis, the co-founder and CEO of DeepMind. Owned by Alphabet Inc., DeepMind is an…

Read More

Elasmogen Inks Research Agreement To Develop New Class Of Therapeutics

By | Biotech, Client news, Knowledge, Life Sciences, Startups

Congratulations to our client Elasmogen! Elasmogen, a spin-out from Aberdeen University, alongside Canada based Feldan Therapeutics, have announced a research agreement with Amgen to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities of Feldan’s Shuttle platform and Elasmogen’s soloMER™ technology to develop the delivery system and binding domains for two undisclosed intracellular targets for Amgen. Elasmogen develops new medicines based on antibody-like molecules isolated from sharks, called VNARs (variable new-antigen receptors). VNARs are found in sharks as part of their immune system and have a similar protective role to antibodies present in the human body. The…

Read More

MyBuilder Acquired by HomeAdivsor

By | Client news, Current Affairs, Entrepreneurs, Investor and VC News, M&A, Startups

We ended March on a high note with some great M&A news for our client MyBuilder. The UK company was recently acquired by HomeAdvisor, an IAC company (NASDAQ: IAC) considered one of the largest home marketplaces in the world. JAG Shaw Baker represented the interests of MyBuilder and its investors, including the founder. This deal is a great example of JAG Shaw Baker’s expertise in creating the right balance between the interests of the selling parties to generate a sensible sell-side proposition to then deliver the sale to the buyer. The firm is proud to have been a part of this deal which was effectively done in a sharp two week period. According…

Read More

Parkinson’s UK Partners With Sheffield University To Create New Spin Out

By | Biotech, Client news, Life Sciences, Startups

Our client, Parkinson’s UK, has just inked a deal with Sheffield University to create a new £1million virtual biotech company, Keapstone Therapeutics. Even though charities and academia have entered into research partnerships before, the partnership between Parkinson’s UK and Sheffield is the first time a charity has approached researchers to launch a spin-out company with the agenda to advance a particular research programme. The Life Sciences team at JAG Shaw Baker has extensive experience with spin-out companies. The team was instrumental in structuring Keapstone Therapeutics in a way that aligned with Parkinson UK’s over-arching charitable objectives, the academic principles of Sheffield University and the requirements of a high-growth company. The…

Read More

Upscale Class of 2017

By | Client news, Current Affairs, Entrepreneurs, Investor and VC News, investors, Startups

We’re happy to round out this week with a big congratulations to the start-ups that are part of Tech City UK’s Upscale Class of 2017. Upscale is a program for the most promising early stage start-ups to begin their journey to success. Each of the 33 companies are mentored by some of the UK’s most successful tech entrepreneurs including Riccardo Zacconi (KING.com/Candy Crush founder); Martha Lane Fox and Brent Hoberman (Lastminute.com founders); Lesley Eccles, (FanDuel founder); and David Buttress (Just Eat founder). The start-ups in Upscale are from a wide variety of tech sectors. The companies also reflect the UK’s strength in particular markets,…

Read More

Monese Raises $10M A Round From International Investors

By | Client news, Current Affairs, Entrepreneurs, Investor and VC News, investors

In one of the first rounds of 2017 and another win for Fintech, Monese, a banking app for immigrants and expats, announced a hefty A round of $10 million. The app caters to immigrants and expats and in the context of Brexit, the round is notable because of its international consortium of investors. Two lead investors, Estonia’s Smart Cap (in the first round with Seedcamp) and Korea Investment Partners (in this current round) are our clients and we’re pleased to have advised them on this deal. Other investors in the round include Anthemis Exponential Ventures and STE Capital. The total funds raised…

Read More

Client News: Doctify Raises Series A Funding Round

By | Client news, Entrepreneurs, Investor and VC News, Startups

Congratulations to our client Doctify Limited on raising more than $1M in their Series A funding round led by Amadeus Capital. We advised Doctify from their inception and their initial seed funding through to their Series A funding.  It’s been exciting to see their success from the start! Doctify is a new healthcare booking platform that gives patients a tool to search for specialist doctors, compare reviews and prices and book online appointments.  In a January article in the Evening Standard, the company says it aims to become the go-to online health platform.

Read More

A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information

INFORMATION ABOUT OUR USE OF COOKIES Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience and also allows us to improve our website. By continuing to browse the website, you are agreeing to our use of cookies. A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. We use the following cookies: • Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page. • Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB. COOKIE DURATION The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime. You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website. Contact If you have any queries regarding this cookie policy please contact us at info@jagshawbaker.com.

Close